Literature DB >> 32278476

NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm.

Daniel D Wong1, Ana Cristina Vargas2, Fiona Bonar3, Fiona Maclean4, Joseph Kattampallil5, Colin Stewart6, Ban Sulaiman7, Leonardo Santos7, Anthony J Gill8.   

Abstract

Oncogenic fusions involving neurotrophic receptor tyrosine kinase (NTRK) genes are being increasingly identified in a range of mesenchymal tumours unrelated to infantile fibrosarcoma or cellular congenital mesoblastic nephroma, where the canonical ETV6-NTRK3 fusion was first described more than two decades ago. Recognition of these NTRK-rearranged tumours poses a diagnostic challenge to surgical pathologists due to their non-specific clinical and pathological features. However, their recognition is of heightened importance, particularly in locally advanced and metastatic sarcomas, due to the recent availability of selective and highly effective targeted therapy. Herein, we present an Australian multi-institutional series of six of these rare NTRK-rearranged mesenchymal neoplasms to share the local experience and diagnostic challenges as well as to highlight key morphological patterns and immunoprofiles that provide the most helpful clues in routine practice. We also propose a diagnostic algorithm for the detection of these fusions, drawing attention to the limitations of ancillary studies including immunohistochemistry against tropomyosin receptor kinase (TRK) protein, fluorescence in situ hybridisation (FISH) and next generation sequencing.
Copyright © 2020 Royal College of Pathologists of Australasia. All rights reserved.

Entities:  

Keywords:  NTRK; TRK; entrectinib; larotrectinib; mesenchymal tumours; pan-TRK; sarcoma; soft tissue tumours

Mesh:

Substances:

Year:  2020        PMID: 32278476     DOI: 10.1016/j.pathol.2020.02.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  6 in total

1.  NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification.

Authors:  Danielle C Costigan; Marisa R Nucci; Brendan C Dickson; Martin C Chang; Sharon Song; Lynette M Sholl; Jason L Hornick; Christopher D M Fletcher; David L Kolin
Journal:  Am J Surg Pathol       Date:  2022-06-20       Impact factor: 6.298

2.  Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.

Authors:  Jen-Wei Tsai; Jen-Chieh Lee; Tsung-Han Hsieh; Shih-Chiang Huang; Pei-Hang Lee; Ting-Ting Liu; Yu-Chien Kao; Ching-Di Chang; Te-Fu Weng; Chien-Feng Li; Jung-Chia Lin; Cher-Wei Liang; Yu-Li Su; Ian Yi-Feng Chang; Yu-Ting Wang; Nien-Yi Chang; Shih-Chen Yu; Jui-Chu Wang; Hsuan-Ying Huang
Journal:  Mod Pathol       Date:  2022-02-11       Impact factor: 8.209

3.  NTRK-Fusion Sarcoma of the Uterine Cervix: Report of 2 Cases With Comparative Clinicopathologic Features.

Authors:  Neshat Nilforoushan; Stephanie L Wethington; Hiro Nonogaki; John Gross; Russell Vang; Deyin Xing
Journal:  Int J Gynecol Pathol       Date:  2021-10-29       Impact factor: 3.326

4.  EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.

Authors:  Xiaohe Dang; Tao Xiang; Can Zhao; Hao Tang; Pengfei Cui
Journal:  Front Med (Lausanne)       Date:  2022-04-28

5.  Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.

Authors:  D Gwyn Bebb; Shantanu Banerji; Normand Blais; Patrice Desmeules; Sharlene Gill; Andrea Grin; Harriet Feilotter; Aaron R Hansen; Martin Hyrcza; Monika Krzyzanowska; Barbara Melosky; Jonathan Noujaim; Bibiana Purgina; Dean Ruether; Christine E Simmons; Denis Soulieres; Emina Emilia Torlakovic; Ming-Sound Tsao
Journal:  Curr Oncol       Date:  2021-01-15       Impact factor: 3.677

6.  NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.

Authors:  Filippo Nozzoli; Alexander J Lazar; Francesca Castiglione; Domenico Andrea Campanacci; Giovanni Beltrami; Francesco De Logu; Chiara Caporalini; Daniela Massi; Giandomenico Roviello
Journal:  Pathol Oncol Res       Date:  2022-02-28       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.